Efficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to reduce hemoglobin A1c (HbA1c) in patients with type 2 diabetes, but the reduction varies between patients and adequate glycemic control may not be achieved. We evaluated the efficacy and safety of the DPP-4 inhibitor alogliptin...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Med Res
Autors principals: Takeda, Hiroshi, Sasai, Nobuo, Ito, Shogo, Obana, Mitsuo, Takuma, Tetsuo, Takai, Masahiko, Kaneshige, Hideaki, Machimura, Hideo, Kanamori, Akira, Nakajima, Kazumi, Matsuba, Ikuro
Format: Artigo
Idioma:Inglês
Publicat: Elmer Press 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701069/
https://ncbi.nlm.nih.gov/pubmed/26767082
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14740/jocmr2418w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars